International Biophysics Corporation has published a new paper, Lung function improvement with AffloVest HFCWO use: a clinician’s perspective on PFT score data from 12 patients with cystic fibrosis.
Patient PFT data was collected by Michelle W. Tackett, RRT and Vivian P. Henderson, RRT, Knoxville, Tennessee. Twelve patients using the AffloVest by International Biophysics for periods ranging from less than a month to almost a full year experienced increases in Pulmonary Function Test (PFT) scores based on measurements taken before and after treatment with the AffloVest. Average FVC, FEV1, and FEF 25-75% increased 15.22%, 17.41%, and 11.21% respectively with the AffloVest.
H. David Shockley, Jr, International Biophysics’ CEO, “This new data demonstrates once again the improved pulmonary outcomes seen with AffloVest use in patients with severe respiratory conditions.”
AffloVest is the first completely self-contained, battery operated, portable High Frequency Chest Wall Oscillation (HFCWO) device that provides critical therapy for people with Cystic Fibrosis, Bronchiectasis and other respiratory diseases.
Shockley adds, “International Biophysics continues to focus on bringing innovative, disruptive medical devices and technologies to market that improve treatment therapies and patient outcomes. We are very happy to know that our technology is helping patients benefit from improvement in their lung function. We expect to see increased clinician adoption of AffloVest technology in their patient’s airway clearance therapy.”
An independent study last year in 2015 was conducted by Michael Cooper, a Registered Respiratory Therapist at one of the leading pediatric respiratory care clinics in the country. Cooper found that improved FEV1, FEF and FVC Ratios for all the patients together was over 10%. This latest paper reconfirms patient lung function improvement with a different set of patients in a different part of the country. The data in both papers demonstrates that patients can have better outcomes when using the AffloVest.